We recently reported that, following induction of clumps of pluripotent H1 human embryonic stem cells (hESCs) with activin-A and Bmp4 in defined medium for 5 days, widespread differentiation of rhythmically contracting cardiomyocytes occurs within 3-4 weeks. In this study, the same approach was used to assess whether human induced pluripotent stem cells (hiPSCs), which may theoretically provide an unlimited source of patientmatched cells for transplantation therapy, can similarly undergo cardiomyocyte differentiation. Differentiation of four pluripotent cell lines (H1 and H9 hESCs and C2a and C6a hiPSCs) was compared in parallel by monitoring rhythmic contraction, morphologic differentiation, and expression of cardiomyogenic genes. Based on expression of the cardiomyogenic lineage markers MESP1, ISL1, and NKX2-5, all four cell lines were induced into the cardiomyogenic lineage. However, in contrast to the widespread appearance of striations and rhythmic contractility seen in H9 and especially in H1 hESCs, both hiPSC lines exhibited poor terminal differentiation. These findings suggest that refined modes of generating hiPSCs, as well as of inducing cardiomyogenesis in them, may be required to fulfill their potential as agents of cardiac regeneration.
for therapeutic use of hESCs is hampered by ethical issues, immune rejection of allogeneic grafts, and oncogenic risk. The first two of these issues may have been recently resolved by the ability to induce pluripotent stem cells (hiPSCs) from human dermal fibroblasts via transduction of pluripotency factors encoded in retroviral vectors (13, 15) . Similar to hESCs, hiPSCs exhibit indefinite self-renewal and the ability to differentiate into derivatives of all embryonic germ layers. Hence, hiPSCs theoretically enable cell replacement therapy using patient-matched cells. In addition, disease-matched hiPSC lines have enabled studies to determine the influence of genetic background on the differentiation of specific cell types, for example, in the instance of a congenital heart defect that causes hypertrophic cardiomyopathy (1).
Despite these advances, the issue of oncogenic risk remains, which is conversely related to the ability to efficiently induce pluripotent cells to specific differentiated endpoints. Current methods to induce cardiomyocytes when initiated in embryoid bodies (EBs) are only 50-70%
INTRODUCTION
Two distinct characteristics define pluripotent stem cells: self-renewal and ability to differentiate into derivatives of all three embryonic germ layers. Thus, virtually any cell type in the body can be derived from pluripotent stem cells. Therefore, pluripotent stem cells have immense potential for various applications. For example, pluripotent cells may serve as an in vitro model for cell differentiation, which may be particularly useful for elucidating the earliest steps of cardiomyocyte differentiation since this process occurs during the earliest stages of embryonic development when tissue quantities are sparse. Also, derivatives of pluripotent cells, which are capable of differentiation into rhythmically contractile cardiomyocytes (3, 11, 16) and can be modified to increase avidity for engraftment into sites of infarction (17), may provide a robust source of human cells for transplantation therapy.
Until recently, lines of pluripotent cells derived from human embryos [human embryonic stem cells (hESCs)] have been most widely investigated. However, the potential efficient (2). Hence, the twofold challenge of efficiently inducing cardiomyocytes and demonstrating that hiPSCs possess the cardiomyogenic potential of hESCs remains. Although it has been reported that mouse (4,5,7,10) and human (16,18) iPSCs can emulate ESCs in this regard, these studies utilized the embryoid body (EB) differentiation model wherein multiple cell types spontaneously appear and in which the extent of cardiomyocyte differentiation is highly variable. Using a non-EB directeddifferentiation format, we recently demonstrated that H1 hESCs, when exposed to factors that induce heart development in the embryo, can differentiate into rhythmically contracting cardiomyocytes within 2 weeks (11). Using the same approach, we have compared the extent of cardiomyogenic differentiation in H1 hESCs with H9 hESCs and with two lines of lentivirus-generated hiPSCs. Although biochemical evidence of cardiomyogenesis was similar in all four cell lines, terminal differentiation into cardiomyocytes exhibiting well-defined sarcomeres and rhythmic contractions was most pronounced in H1 and H9 hESCs.
MATERIALS AND METHODS

hESCs and hiPSCs
Human ESC lines H1 and H9 (14) were purchased from the National Stem Cell Bank (NSCB; WiCell, Madison, WI). Induced pluripotent stem cell lines C2a and C6a were induced from human foreskin fibroblasts (ATC #CRL2097) as previously described (12) by transduction with lentivirusencoded octamer-binding transcription factor 4 (Oct4), sex-determining region Y box 2 (Sox2), Nanog, and Lin28. Pluripotent cells were maintained under hypoxic conditions (4% O 2 , 5% CO 2 ) on mouse embryonic fibroblasts (MEFs) inactivated with mitomycin C (#M0503; SigmaAldrich, St. Louis, MO), in medium consisting of DMEM/ F12 (#11330-032, Invitrogen, Carlsbad, CA) supplemented with 20% knockout serum replacement (#10828-028; Invitrogen), 1% nonessential amino acids (#11140-050, Invitrogen), 1% penicillin-streptomycin (#15140-148, Invitrogen), l-glutamine (#25030-081, Invitrogen), 100 µM b-mercaptoethanol (#M-6250, Sigma-Aldrich), and 4 ng/ml human recombinant basic fibroblast growth factor (#PHG0026, AA 10-155, Invitrogen). Colonies of hESCs and hiPSCs were passaged every 5 days by manual microdissection with a 27-gauge needle to create 500-µm 2 clumps, followed by a 1 à 4 split. The experiments described in this article employed H1 and H9 hESCs at passage 36 and C2a and C6a hiPSCs at passage 29.
Induction of Cardiomyocyte Differentiation
To differentiate pluripotent cells into cardiomyocytes, we used "directed differentiation," as previously described (11). Briefly, colonies were mechanically dissected into small clumps that were plated onto wells of a six-well dish (without MEFs) that had been precoated with reduced growth factor Matrigel (354230; BDBiosciences, San Jose, CA) at a final concentration of 0.05 mg/ml in DMEM/F12; counting of cells dissociated from clumps estimated that each well contained 250,000 cells. For the next 7 days, pluripotency was maintained under hypoxic conditions using hESC medium that had been conditioned by MEFs during the previous 24-h period (i.e., MEF-conditioned medium). To induce differentiation, medium was exchanged for RPMI medium 1640 (#22400, Invitrogen) fortified with B-27 serumfree supplement (#17504-044, Invitrogen, which contains a proprietary amount of insulin), supplemented with activin-A (50 ng/ml; #338-AC, R&D Systems, Minneapolis, MN) and bone morphogenetic protein 4 (BMP4; 10 ng/ml; 314-BP-010, R&D Systems), and the cultures were placed in normoxic conditions; this time point is referred to as "day 0." After 5 days of induction with activin-A and BMP, these growth factors were removed and differentiation was continued in RPMI/B27/ insulin alone. Cultures were monitored daily for the onset of spontaneous contractions.
Immunostaining
Cardiomyocytes derived from hESCs and hiPSCs were characterized by immunostaining 40 days after inducing differentiation. Cells were fixed in 1% paraformaldehyde for 1 h and permeabilized with 0.5% Triton X-100 for 30 min. Cultures were rinsed 3´ with PBS, blocked with 3% bovine serum albumin (BSA)/ PBS, followed by 3´ rinses with PBS. Primary antibodies prepared in 1% BSA/PBS were applied overnight at 4°C. The following primary antibodies were used: antia-actinin (1:100; A37732, Sigma), anti-cardiac troponin T (cTnT; 1:100; AMPA6687, Thermo Scientific, Rockford, IL), and anti-titin (1:200; 9D10, Developmental Studies Hybridoma Bank, Iowa City, IA). Primary antibodies were rinsed 3´ with PBS, followed by application of an appropriate secondary antibody labeled with Alexa Fluor 488 (1:1,000; A21202 Invitrogen). Secondary antibodies diluted in 1% BSA/PBS were applied for 2 h on a rotator. Cells were rinsed 3´ with PBS, and nuclei were stained with TOPRO-3 (1:1,000; T3605, Invitrogen) for 10 min. Images were acquired using a laser-scanning confocal microscope (Eclipse TE2000-U; Nikon, Tokyo, Japan) and analyzed using MetaMorph 6.2 software (Universal Imaging, West Chester, PA).
Real-Time PCR
Expression of genes expressed during cardiomyogenic differentiation was assessed by real-time quantitative PCR (qPCR). Beginning at the time of induction (day 0), cells were harvested on alternate days during the first 20 days, followed by harvest of a terminal time point on day 40. RNA purification and qPCR were performed as previously described (11). Briefly, cells were lysed, vigorously pipetted, and stored at -80°C until purification. Immediately after thawing, total RNA was purified using the RNeasy Mini Kit (#74104, Qiagen, Valencia, CA), with Qiashredder (#79654, Qiagen), as per the manufacturer's instructions. Following quantification at A 260 , 1.0 µg total RNA from each sample was reverse-transcribed (#C-03 RT 2 First Strand Kit, SABiosciences, Frederick, MD). qPCR was performed by adding 10 µl of each RT product to 90 µl master mix (#PA-011 RT 2 SYBR Green/ Fluorescein qPCR Master Mix, SABiosciences) in wells of 96-well plates containing custom prearrayed primer pairs (Custom RT 2 Profiler PCR Array, SABiosciences). PCR reactions were performed using an iCycler (BioRad, Hercules, CA).
RESULTS
Differentiation of Beating Cardiomyocytes Is More Extensive in hESCs Than in hiPSCs
We simultaneously compared the ability of two widely used hESC lines (H1 and H9) and two hiPSC (C2a and C6a) lines to differentiate into beating cardiomyocytes, using identical conditions of induction and cell culture. As described in the Supplemental Figure 4 of , pluripotent C2a and C6a hhiPSCs exhibit morphologic, gene expression, and karyotype characteristics that are indistinguishable from pluripotent H9 hESCs. Moreover, C2a and C6a hiPSCs form teratomas that contain cells from all three germ layers. And C2a and C6a hiPSCs can reproducibly and efficiently differentiate into hepatocytes in stepwise, directed fashion by sequential treatment with growth factors that induce liver development in the embryo (12).
In this study, all four lines were induced to differentiate in defined medium (RPMI/B27) supplemented with cardiomyogenic growth factors BMP4 and activin-A at time zero (day 0) for 5 days, after which the cells were treated with RPMI/B27 only, up to day 40. The experimental scheme is depicted in Figure 1 . Although rhythmic beating was observed by day 10 in both hESC lines, contractions that were relatively sporadic were not observed in the hiPSC lines until the fourth week. In all lines, contractions were spontaneous and rhythmic, always occurring in cell clusters rather than in individual cells, which is characteristic of cardiomyocytes derived from pluripotent cells (3,9). Figure 2 shows characteristic morphologies of cultures derived from each cell line at day 40. Corresponding videos showing the extent of rhythmic contractions in culture dishes on day 40 are presented as Video Clips 1-4, which can be viewed by accessing the following link: http://www.mcw.edu/ cellbiology/johnloughphd.htm. In some instances (H1 hESCs), contractions were sustained for a year or longer (not shown). Contractility was most extensive in H1 hESC cultures, wherein multilayered networks of contracting cells formed that were interconnected, nearly spanning the entire dish (Video Clip 1); in accord with our previous experience using H1 cells, this indicated that the contractile tissue was comprised of contiguous myocytes that were electrophysiologically synchronized (11). H9 hESCs also exhibited contractile three-dimensional areas (Video Clip 2); however, these were neither as networked nor as extensive as in cultured H1 hESCs. By contrast, cultures containing hiPSC lines C2a and C6a exhibited beating in only a few clumps of cells that were not interconnected (Video Clips 3 and 4); with time, contractile areas in hiPSC cultures did not expand or become multilayered, in contrast to H1 and H9 hESCs.
Sarcomere Differentiation Is More Extensive in hESCs Than in hiPSCs
Immunostaining was performed 40 days after inducing differentiation to monitor the presence of cardiacspecific proteins and their assembly into sarcomeres. All panels of Figure 3 show immunostaining patterns in rhythmically beating areas of the dish. This revealed that cTnT and sarcomeric a-actinin were organized into striated patterns in H1 and H9 hESCs (Fig. 3a-f ). However, striations in both hiPSC lines (Fig. 3h, k) were less conspicuous and not as widespread as in the hESC cultures, consistent with the abundance of beating clusters shown in the video clips (http://www.mcw.edu/ cellbiology/johnloughphd.htm). It is also note worthy that the titin immunostaining pattern was remarkably extensive only for H1 hESCs (Fig. 3m, n) , which displayed three-dimensional organization of sarcomeric structures. These characteristics were less evident in H9 hESCs and were almost completely absent in contractile areas of C2a and C6a hiPSCs (not shown).
qPCR Monitoring of Marker Gene Expression
Although percentages of immunostained cells could not be enumerated due to extensive cellular multilayering, expression of selected mRNAs was monitored by qPCR at multiple points during the differentiation period (Fig. 4) . In all four lines, induction of differentiation at day 0 was followed by diminishing levels of the pluripotency marker OCT4, concomitant with transient expression of the mesendoderm marker brachury [T, T-box-1 (Tbx1)]; this pattern was anticipated for these markers. The earliest phases of cardiomyogenic induction are characterized by expression of mesoderm posterior 1 homolog (MESP1), NK2 homeobox 5 (NKX2.5), and insulin gene enhancer protein (ISL1); expression of these markers was similar in all lines, except that expression of ISL1 was low in both hiPSC lines but remarkably high in H9 hESCs. As cardiomyocytes begin to terminally differentiate, they express mRNAS including GATA4, myocyte enhancer factor 2C (MEF2C), cardiac troponin T type 2 (TNNT2), TBX20, and myosin light chain 7 (MYL7). Although these markers increased as expected during the second week of the 40-day culture period, expression of TNNT2, TBX20, and MYL7 was remarkably low in both hiPSC lines. Expression of mRNAs encoding various ion channel genes [hyperpolarization activated cyclic nucleotidegated potassium channel 4 (HCN4), voltage-gated sodium channel type 5 a subunit (SCN5A), voltage-gated calcium channel L type a1c subunit (CACNA1C), voltage-gated potassium channel, subfamily H2 (KCNH2), potassium inwardly rectifying channel, subfamily J2 (KCNJ2), voltage-gated potassium channel, Shal-related subfamily 3 (KCND3)] was also monitored, revealing that, with the exception of HCN4 that peaked in all lines at day 6, all began to undergo steady, subtle increases late in the second week; however, no cell line-specific differences were noted. Finally, expression of mRNAs indicative of differentiation into ectodermal [paired box 6 (PAX6)] and endodermal (SOX17) lineages revealed that, whereas all four lines exhibited strong SOX17 expression (300´-800´) during the first week, induction of ectoderm was minimal, with the exception of increased PAX6 levels in C2a hiPSCs on days 4-12 and inexplicably on day 40.
DISCUSSION
We simultaneously compared the cardiomyogenic potential of two human iPSC lines with two wellcharacterized human ESC lines, under controlled conditions using a directed differentiation protocol. We show that cells from all four pluripotent stem cell lines can differentiate toward a cardiomyocyte fate. However, H1 hESCs exhibited the most cardiomyogenic competence, forming extensive areas of rhythmically contractile cells (Video Clips 1-4) that contained organized sarcomeres (Fig. 3) . Accordingly, in terms of biochemical differentiation, qPCR revealed that H1 cells were the most robust in terms of cardiomyogenic gene expression (Fig. 4) .
Several groups have reported that human and mouse iPSCs possess cardiomyogenic competence (4, 5, 7, 10, 16, 18) . Relative to our findings, those of Zhang et al. (16) are most noteworthy because these investigators compared differentiation of H1 and H9 hESCs with two different lines of lentivirus-induced human iPSCs, observing that sarcomere organization and expression of cardiomyogenic genes were indistinguishable in hiPSCs and hESCs, although the ability to contract was highest in H9 hESCs. Despite similarities in approach, it is difficult to compare their findings with those described here since Zhang et al. (16) used an embryoid body (EB) rather than a directed differentiation format and because their gene expression analysis was based on a single endpoint determination. Regarding the relative competence of H1 and H9 hESCs, differences in cardiomyogenic potency have previously been noted, attributed to epigenetic marks (6,8); other reports have indicated that cardiomyocytes are most successfully differentiated from H1 [this article and (11)], H7 (3), or H9 (16) hESCs. These differences are possibly related to differences in spontaneous differentiation that we noted during expansion and passaging of the pluripotent cells used in this study. Specifically, spontaneous differentiation in H1 hESCs was minimal during more than 50 passages, in contrast with H9 hESCs, which exhibited differentiation after only seven passages. Both hiPSC lines displayed even greater propensity to spontaneously differentiate, requiring the establishment of fresh colonies after every fourth passage. Although epigenetic factors may have influenced these disparate results, differences in cell culture format and induction conditions, for example, directed differentiation versus the EB format, also affect differentiated outcomes. Therefore, while the results described here indicate that both of the hESC and hiPSC lines can enter the cardiomyogenic pathway while only the hESC lines exhibited substantial terminal differentiation, such a conclusion must remain tentative until universal conditions are established, which are capable of efficiently, reproducibly, and rapidly inducing pluripotent cells to terminally differentiated cardiomyogenic endpoints.
Regarding the limited ability of C2a and C6a hiPSCs to differentiate into functional cardiomyocytes, the possibility that differentiation is suppressed due to the integration of pluripotency genes in lentivirus-induced hiPSCs has been previously noted (16). However, the decline of Oct4 expression in C2a and C6a cells was essentially equivalent to that observed in H1 and H9 hESCs (Fig. 4) . Moreover, evidence that C2a hiPSCs are differentiationcompetent was recently demonstrated by the equivalent ability of C2a hiPSCs and H9 hESCs to undergo growth factor-directed differentiation into mature hepatocytes, with efficiency exceeding 80% (12). Although the relative inability of hiPSCs to undergo terminal myocyte differentiation is unexplained, it is noted that the highly efficient differentiation of hepatocytes was performed in monolayer culture format wherein all cells are exposed to equivalent growth factor levels, in contradistinction to the induction of pluripotent cells organized in threedimensional clumps as employed here. It is therefore speculated that the limited ability of hiPSCs to terminally differentiate may indicate that, while initial cardiomyogenic signals in clumped cells were sufficient to overcome the presence of integrated pluripotency genes, signals regulating terminal differentiation were somehow compromised. It is nonetheless encouraging cells in C2a and C6a cultures expressed cardiomyogenic RNAs, suggesting that these cells occupy a position in the cardiomyogenic pathway from which improved signaling may support terminal differentiation. In this regard, we are currently inducing pluripotent cells maintained in monolayer culture, with the goal of establishing conditions that mimic the high levels of efficiency that have been reproducibly achieved during hepatocyte differentiation (12).
